event tracking

International Linked Clinical Trials (iLCT)

23 results.

October 18, 2024 3 big takeaways from Grand Challenges in Parkinson’s Disease

In September, Van Andel Institute welcomed nearly 300 scientists, physicians and people with Parkinson’s for our annual Grand Challenges in Parkinson’s Disease symposium and Rallying…

April 3, 2024 Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results

LONDON (April 3, 2024) — Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may…

February 23, 2024 Cure Parkinson's and Van Andel Institute fund Phase 2 clinical trial of dapansutrile for Parkinson’s

LONDON (Feb. 23, 2024) — Cure Parkinson’s and Van Andel Institute are delighted to announce funding for a Phase 2 clinical trial…

August 28, 2023 Preliminary phase 2 trial results of lixisenatide presented

Copenhagen, Denmark (August 28, 2023) — A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate…

March 13, 2023 Van Andel Institute, Cure Parkinson’s renew $4.5 million co-funding agreement to support collaborative Parkinson’s clinical trials program

Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…

January 10, 2023 Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease

London, United Kingdom (Jan. 10, 2023) — Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol,…

April 5, 2022 Top-line results reported from clinical trial of diabetes drug in Parkinson’s

This release has been republished from Cure Parkinson’s. Researchers from Cedars Sinai Hospital, Los Angeles, have presented their initial top line results of